Hybridon
Executive Summary
Antisense firm raises "an aggregate of $20 mil." in two private sales of convertible preferred stock to U.S. and foreign investors. In addition, Hoffmann-La Roche took a $4 mil. equity position in the company. On Feb. 4, Roche signed an agreement to fund Hybridon research on hepatitis B and C and human papilloma virus, a deal that also involved an equity purchase ("The Pink Sheet" Feb. 15, 1992, T&G-7). Hybridon says it "has completed and expects to announce a second partnership with a multinational pharmaceutical company" and the "total value of the two collaborations" will be over $50 mil.